Fairvalue-Calculator Fairvalue-Calculator
EN DE

Actinium Pharmaceuticals, Inc (ATNM) Fair Value & Analysis

Healthcare · US · Market cap $32.0M

Price$1.02
Fair Value$1.12
Upside+9.8%
Quality95/100
Evidence: Low Range $0.8400 – $1.40

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Actinium Pharmaceuticals, Inc (ATNM) currently trades at $1.02, while our model-based Fair Value estimate is $1.12 — implying the stock looks roughly 9.8% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/3 Trial; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a antibody radioconjugate that deliver alpha-emitter Ac-225 to prostate cancer cells. In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia. Further, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies, and its research…

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -84% Regeneron Pharmaceuticals, Inc (REGN) +109% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -64%

Frequently asked questions

Is Actinium Pharmaceuticals, Inc (ATNM) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $1.12 versus a price of $1.02 — about +10% (undervalued). Model-based estimate, not financial advice.
What is the fair value of ATNM?
Our 21-model fair value for Actinium Pharmaceuticals, Inc is $1.12 (as of Jun 24, 2026), built from audited fundamentals. The current price is $1.02.
What is the quality score of ATNM?
Actinium Pharmaceuticals, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.